WaveMan
WaveMan · Company
CLRB · Cellectar Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CLRB Cellectar Biosciences (CLRB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001279704
Quote by TradingView
C-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
20
13F, latest reported quarter

What the filings say about CLRB

Insiders, 180 days
+$50.0K net bought
2 buyers

Cellectar Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Cellectar Biosciences, Inc. insiders bought a net $50.0K of stock across 9 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Longcor Jarrod
Chief Operating Officer
BUY
2026-05-11 SECtraded 2026-05-07
8,680
$25.0K
-58.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 2, 2025.
  • +7.4% median (+7.4% mean) 90-day return after 2 previous buys.
  • The trade is 42.4% of the 20,451 shares held after it.
  • 1 other insider bought within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Longcor Jarrod bought about $25.0K of CLRB on May 7, 2026; 1 other insider bought within 30 days and 20 funds added in the latest 13F quarter.
CARUSO JAMES V
Chief Executive Officer
BUY
2026-05-11 SECtraded 2026-05-07
8,680
$25.0K
-58.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 2, 2025.
  • The trade is 42.7% of the 20,318 shares held after it.
  • 1 other insider bought within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer CARUSO JAMES V bought about $25.0K of CLRB on May 7, 2026; 1 other insider bought within 30 days and 20 funds added in the latest 13F quarter.
NEIS JOHN
Director
SELL
2025-12-16 SECtraded 2025-12-12
198
$733
-55.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1980.0% of the 10 shares held after it.
  • No other insider sold within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NEIS JOHN sold about $733 of CLRB on Dec 12, 2025, the largest insider sale at the company on our record; 20 funds added in the latest 13F quarter.
CARUSO JAMES V
Chief Executive Officer
BUY
2025-07-03 SECtraded 2025-07-02
10,000
$49.9K
-74.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 85.9% of the 11,638 shares held after it.
  • 2 other insiders bought within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer CARUSO JAMES V bought about $49.9K of CLRB on Jul 2, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 20 funds added in the latest 13F quarter.
Longcor Jarrod
Chief Operating Officer
BUY
2025-07-03 SECtraded 2025-07-02
10,000
$49.9K
-74.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 10, 2025.
  • The trade is 78.3% of the 12,768 shares held after it.
  • 2 other insiders bought within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Longcor Jarrod bought about $49.9K of CLRB on Jul 2, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 20 funds added in the latest 13F quarter.
9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 4 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$50.0K over 180 days
more than 73% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
20 funds bought in last quarter
below 68% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.8% of the float short (float per yahoo 2026-10-26) · 2.0 days to cover · settled 2026-09-30
below 67% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CLRB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-68.0%12M
-70%-45%-19%+7%2025-102025-122026-022026-042026-062026-082026-10 2026-05-07 · Longcor Jarrod bought $25.0K2026-05-07 · CARUSO JAMES V bought $25.0K2025-12-12 · NEIS JOHN sold $733
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CLRB: institutional holders (13F)

13F holdings, latest reported quarter
Caligan Partners LP
469,998 sh
$1.3M
Nantahala Capital Management, LLC
439,996 sh
$1.2M
STEMPOINT CAPITAL LP
354,938 sh
$986.7K
VANGUARD CAPITAL MANAGEMENT LLC
327,367 sh
$910.1K
SILVERARC CAPITAL MANAGEMENT, LLC
321,728 sh
$894.4K

Congress trades in CLRB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CLRB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CLRB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$398.2K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$84.7K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$511.9K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$17.7K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$6.5K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$628 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
3 active
1
Phase 2
1 active
1
Phase 3
1 active
What changed recently
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory
2026-10-01 · Completion moved 2026-05 → 2027-06-30
Phase 1
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Inclu
2026-10-01 · Completion moved 2026-08-25 → 2027-06-30
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $50.0K bought by insiders over 180 days, 20 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CLRB financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-124.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-88.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-120.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122023-09
Operating income-$23.0M-$51.8M-$39.0Mn/a
Net income-$21.8M-$44.6M-$38.0Mn/a
EPS (diluted)-8.35-41.89-3.50n/a
Operating cash flow-$23.1M-$47.6M-$32.4Mn/a
Cash$13.2M$23.3M$9.6M$19.0M
SEC XBRL, fiscal years, as known on 2026-10-28

CLRB Stock Sonar score 4/7 axes

Find similar shapesCompare

CLRB ranks highest on insider conviction (76th percentile) and risk and compliance (75th), and lowest on profitability (25th), among Pharma & Biotech peers.

Profitability
25
Inputs
  • Return on equity-124.2% · 27 pct, sector of 545
  • Return on assets-88.7% · 27 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-120.0% · 20 pct, sector of 576
Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$50K · 72 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Institutional and government
32
Inputs
  • Funds adding, latest quarter20 · 32 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
75
Inputs
  • Short interest, % of float+1.8% · 75 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CLRB filings, in plain words

Are Cellectar Biosciences insiders buying or selling CLRB?

In the 180 days to 2026-10-28, Cellectar Biosciences insiders were net buyers, a net $50.0K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Cellectar Biosciences insiders were net buyers of CLRB, a net $50.0K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies